Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute coronary syndrome israeli surveys data

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tenenbaum, Alexander ^a,b   Medvedofsky, Diego ^a   Fisman, Enrique Z ^b   Bubyr, Liudmila ^a   Matetzky, Shlomi ^a   Tanne, David ^a   Klempfner, Robert ^a   Shemesh, Joseph ^a   Goldenberg, Ilan ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NITRATE; ROSUVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE CORONARY SYNDROME ISRAELI SURVEY REGISTRY; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RECURRENT DISEASE; STENT THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASES; COMORBIDITY; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PATIENT READMISSION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859871458     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035298     Document Type: Article

References (26)

1. (1978) A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40: 1069-1118.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245.
3. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418.
4. (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27.
5. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, et al. (2005) Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165: 1154-1160.
6. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, et al. (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85: 37-45.
7. Tenenbaum A, Fisman EZ, Motro M, Adler Y, (2008) Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 45: 127-53.
8. (2010) ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-74.
9. Behar S, Battler A, Porath A, Leor J, Grossman E, et al. (2003) Israel Heart and Internal Medicine Societies. A prospective national survey of management and clinical outcome of acute myocardial infarction in Israel, 2000. Isr Med Assoc J 5: 249-54.
10. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, et al. (2001) Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 285: 1711-1718.
11. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
12. Tang XL, Sanganalmath SK, Sato H, Bi Q, Hunt G, et al. (2011) Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. PLoS One 6 (9): e25320.
13. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, et al. (2011) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357: 1063-1068.
14. Nusca A, Melfi R, Patti G, Di Sciascio G, (2010) Statin loading for acute coronary syndromes. Curr Opin Cardiol 25: 373-8.
15. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, et al. (2005) National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 h of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96: 611-616.
16. Tenenbaum A, Fisman EZ, (2010) "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 9: 24.
17. Sacks FM, Carey VJ, Fruchart JC, (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363: 692-4.
18. Tenenbaum A, Fisman EZ, (2011) Fibrate use in the United States and Canada. JAMA 306: 157.
19. Jun M, Foote C, Lv J, Neal B, Patel A, et al. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875-84.
20. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338: b92.
21. Goldenberg I, Boyko V, Tenenbaum A, Tanne D, Behar S, et al. (2009) Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 169: 508-14.
22. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, et al. (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260: 641-651.
23. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585-1591.
24. Natarajan P, Ray KK, Cannon CP, (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55: 1283-99.
25. Rosenblit PD, (2012) Do persons with diabetes benefit from combination statin and fibrate therapy? Curr Cardiol Rep 14: 112-24.
26. Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sánchez G, Almeida-Gutiérrez E, Martínez-Gómez DF, et al. (2010) Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. Cir Cir 78: 229-37.